Patent intelligence · US
US 8663694
Taste masked dosage form containing roflumilast
Taste masked dosage form containing roflumilast
Patent details — US 8663694
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 4, 2014
- Expiration
- Feb 27, 2034
- Applicant
- TAKEDA GMBH
- Claims
- 21
- CPC classes
- A61K, A61K31/166, A61K31/44, A61K9/0095
Quick answer
US 8663694 (Taste masked dosage form containing roflumilast) is held by TAKEDA GMBH. Status: granted. Granted Mar 4, 2014. Expires Feb 27, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TAKEDA GMBH
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/166, A61K31/44, A61K9/0095, A61K9/1611, A61K9/1623
More from TAKEDA GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8663694?
US 8663694 (Taste masked dosage form containing roflumilast) is held by TAKEDA GMBH. Status: granted. Granted Mar 4, 2014. Expires Feb 27, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8663694?
TAKEDA GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8663694 expire?
Our index shows an expiration date of Feb 27, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.